News | October 25, 2023
Sumitomo Pharma announces authorization in Canada of Orgovyx for treatment prostate cancer
Orgovyx is the first and only oral GnRH receptor antagonist approved for advanced prostate cancer in Canada
Orgovyx is the first and only oral GnRH receptor antagonist approved for advanced prostate cancer in Canada
Investment is additive to KKR’s existing health care growth strategy
ASMD is highly variable and the age of onset, specific symptoms and severity of the disorder can vary dramatically from one person to another
Approval of oral, once-daily VELSIPITY based on favorable safety and efficacy data from the ELEVATE UC Phase 3 trials
Pant delivers keynote address at National Conclave on “Augmented Zoonotic Diseases Surveillance at Human – Wildlife Interface”
_256_384.jpg)
GenWorks Health Introduces Braster Pro for breast screening & EVA for cervical screening in rural areas & communities
Seamless transition from preclinical to first-in-human trials with EUDRACAP platform technology
Lupin enters into BTA with Lupin Manufacturing Solutions
Punit has more than 20 years of experience in the generics and branded pharmaceutical marketplace
Evonik China and Shandong Vland Biotech agreed to build a joint venture to expand their presence in gut health solutions products for farm animals globally
Subscribe To Our Newsletter & Stay Updated
